Potential drug interactions analysis of COVID-19 patients at a hospital in West Java

Kusumawardani, Larasati Arrum; Maria, Nisa; Fanani, Yumna Nabila

doi:10.20885/jif.vol17.iss2.art8

Cited by 4 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high number of items prescribed is a problem related to polypharmacy, which describes the simultaneous use of multiple drugs. Thus, polypharmacy in public healthcare centers can have negative effects, such as increased patient expenditures [9,12], unwanted side effects [12][13][14][15], drug interactions [16][17][18][19][20][21], healthrelated quality of life [22,23] and in compliance with the treatment [24][25][26]. In this study, polypharmacy was found in some patients with chronic diseases such as hypertension and diabetes mellitus.…”

Section: Prescribing Indicatorsmentioning

confidence: 77%

Prescribing and patient care indicators for drug use evalation at primary healthcare centers in Indonesia

Kusumawardani¹,

Andrajati²,

Lathifatuzahra³

et al. 2023

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

Section: Prescribing Indicatorsmentioning

confidence: 77%

Prescribing and patient care indicators for drug use evalation at primary healthcare centers in Indonesia

Kusumawardani¹,

Andrajati²,

Lathifatuzahra³

et al. 2023

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

“…Tatalaksana pengobatan pada pasien COVID-19 diberikan antivirus, terapi suportif dan terapi simptomatik [8]. Berdasarkan penelitian di Indonesia, pasien COVID-19 menerima 9 obat (polifarmasi) selama di rawat inap [9]. Pasien yang menggunakan obat dalam jumlah banyak (polifarmasi) berpotensi mengalami interaksi obat-obat [10].…”

Section: Pendahuluanunclassified

“…Berdasarkan hasil penelitian di Indonesia potensi interaksi obat pada pasien COVID-19 rawat inap berkisar 54.61% hingga 93.33% [9], [13]. Penelitian di salah satu rumah sakit di Kalimantan Selatan menjelaskan pada pasien COVID-19 ditemukan potensi interaksi obat sebanyak 231 kasus, dengan empat interaksi obat terbesar yaitu Azitromisin -Hidroksikloroquin; Azitromisin -Levofloxacin; Hidroksikloroquin -Levofloxacin; serta Azitromisin -Lovinapir dan Ritonavir [14].…”

Section: Pendahuluanunclassified

“…Berdasarkan kajian Meta Analisis, faktor yang berhubungan dengan terjadinya potensi interaksi obat pada pasien di rumah sakit Ethiopia diperoleh faktor usia, komorbid, jumlah obat yang digunakan selama dirawat dan lama dirawat [15]. Adapun Penelitian di Indonesia menyatakan komorbid, jumlah obat yang digunakan selama dirawat dan lama dirawat merupakan faktor yang berhubungan dengan potensi interaksi obat pada pasien COVID-19 [9].…”

Section: Pendahuluanunclassified

See 1 more Smart Citation

Analisis Faktor yang Berhubungan dengan Potensi Interaksi Obat Pasien Covid-19 di Salah Satu Rumah Sakit Kalimantan Selatan

Sari,

Putra,

Wasiaturrahmah

et al. 2023

J. Sains Kes.

View full text Add to dashboard Cite

Patients with COVID-19 are treated with antivirals, supportive therapy, and symptomatic therapy. COVID-19 patients who use multiple drugs may experience drug interactions. The purpose of this study is to investigate factors associated with potential drug interactions in COVID-19 patients who are hospitalized. This cross-sectional retrospective observational study was carried out in a hospital in the Indonesia. The sample consists of medical records from COVID-19 patients who received therapy and were hospitalized between January and March 2021. The IBM Micromedex website, DrugBank Interaction Checker, and Stockley Drug Interactions 9th Edition are research tools used to assess the potential and mechanism of drug interactions. The results were 82 medical records that were analyzed for potential drug interactions. The proportion of patients who have potential drug interactions is 69.5%. in hospitalized COVID-19 patients. The drug interaction mechanism in COVID-19 patients is potentially in the pharmacokinetics phase. Age (p=0.034; OR 0.327, CI 0.11-0.94), number of drugs used during treatment (p=0.002; OR 14.00, CI 1.76-111.11), and length of stay (p=0.000; OR 0.009, CI 0.001-0.07) were factors associated to potential drug interactions. Subsequently, factors associated with potential drug interactions in COVID-19 hospitalized patients include age, number of drugs used during treatment, and length of stay. Keywords: COVID-19, drug interactions, factors associated, potential Abstrak Tatalaksana pengobatan pada pasien COVID-19 diberikan antivirus, terapi suportif dan terapi simptomatik. Penggunaan beberapa jenis obat tersebut membuat pasien COVID-19 berpotensi mengalami interaksi obat. Penelitian ini bertujuan menganalisis faktor yang berhubungan dengan potensi interaksi obat pada pasien COVID-19 rawat inap di rumah sakit. Penelitian obeservasional retrospektif cross sectional ini dilaksanakan di salah satu rumah sakit Kalimantan Selatan. Sampel yakni rekam medis pasien COVID-19 yang mendapat terapi dan rawat inap di rumah sakit periode Januari-Maret 2021 Instrumen penelitian mengkaji potensi dan mekanisme interaksi obat meliputi situs IBM Micromedex , DrugBank Interaction Checker dan Stockley Drug Interactions 9th Edition. Hasil diperoleh sebanyak 82 rekam medis dianalisis potensi interaksi obat. Persentase pasien mengalami potensi interaksi obat sebesar 69,5%. pada pasien COVID-19 rawat inap di rumah sakit. Mekanisme interaksi obat pada pada pasien COVID-19 pada berpotensi pada fase farmakokinetika. Faktor berhubungan potensi interaksi obat pasien COVID-19 yakni usia (p=0.034; OR 0.327, CI 0.11-0.94), jumlah obat yang digunakan selama dirawat (p=0.002; OR 14.00, CI 1.76-111.11) dan lama dirawat (p=0.000; OR 0.009 , CI 0.001-0.07). Kesimpulan, faktor berhubungan potensi interaksi obat pada pasien COVID-19 rawat inap di rumah sakit meliputi usia, jumlah obat yang digunakan selama dirawat dan lama dirawat. Kata Kunci: COVID-19, faktor berhubungan, interaksi obat, potensi

show abstract

“…The more of drugs used patients, the higher potential for drug interactions (7). The presence of comorbidities in COVID-19 patients results in a longer duration of patient hospitalization and the use of multiple drugs or polypharmacy, thereby increasing the risk of drug interactions (8). Drug interactions with drugs that have the potential to occur in the treatment of COVID-19 comorbid hypertension need to be known because they can cause adverse drug reactions (ADR) thereby increasing the risk of hospitalization, long recovery time, or death in severe cases (9).…”

Section: Introductionmentioning

confidence: 99%

Analysis of Drug Accuracy, Dosage and Drug Interactions in Comorbid Hypertension COVID-19 Patients at Hospital X in Central Java Period 2021

Khairani

Manninda²,

Rosyiedi

2022

int.jour.sci.res.mana.

View full text Add to dashboard Cite

Treatment of COVID-19 comorbid hypertension involves many drugs with therapeutic risk of non-guidelines and potential drug interactions. Study aimed to determine the demographic characteristics, clinical degree, accuracy of drugs and doses and potential drug interactions. Study design was cross-sectional through retrospective data collection. Samples that meet the criteria obtained 70 samples. The results were 51.4% female sample, the highest age was 46-59 y.o (48.6%), the most degree of COVID-19 was moderate (61.4%), the highest degree of hypertension was grade 1 (48.6%) and the longest length of stay was >14 days (51.4%). The accuracy of COVID-19 therapy were 78.6% accurate drug, 21.4% inaccurate drug, and 100% accurate dose. The accuracy of antihypertensive were 82.9% accurate drug, 17.1% inaccurate drug, 95.7% accurate dose and 4.3% inaccurate dose. Samples with potential drug interactions were 97.1%, the highest number of potential drug interactions was 1-5 events (52.9%), based on severity 60.2% moderate, 20.1% minor, 13.2% major, and 6.5% unknown. Correlation test results sig. (p-value) 0.237. The conclusion showed that most samples were female, aged 46-59, moderate-grade COVID-19 patients with grade 1 hypertension, and length of stay >14 days. There is accuracy or inaccuracy of drugs and doses, potential drug interactions and there is no relationship between length of stay and potential drug interactions.

show abstract

Potential drug interactions analysis of COVID-19 patients at a hospital in West Java

Cited by 4 publications

References 20 publications

Prescribing and patient care indicators for drug use evalation at primary healthcare centers in Indonesia

Prescribing and patient care indicators for drug use evalation at primary healthcare centers in Indonesia

Analisis Faktor yang Berhubungan dengan Potensi Interaksi Obat Pasien Covid-19 di Salah Satu Rumah Sakit Kalimantan Selatan

Analysis of Drug Accuracy, Dosage and Drug Interactions in Comorbid Hypertension COVID-19 Patients at Hospital X in Central Java Period 2021

Contact Info

Product

Resources

About